Identification of a Tumor Suppressor Relay Between the FOXP3 and the Hippo Pathways in Breast and Prostate Cancers

Overview

Journal Cancer Res

Specialty Oncology

Date 2011 Feb 1

PMID 21278236

Citations 53

Authors

Weiquan Li

Lizhong Wang

Hiroto Katoh

Runhua Liu

Pan Zheng

Yang Liu

Affiliations

Soon will be listed here.

Abstract

Defective expression of LATS2, a negative regulator of YAP oncoprotein, has been reported in cancer of prostate, breast, liver, brain, and blood origins. However, no transcriptional regulators for the LATS2 gene have been identified. Here we report that spontaneous mutation of the transcription factor FOXP3 reduces expression of the LATS2 gene in mammary epithelial cells. shRNA-mediated silencing of FOXP3 in normal or malignant mammary epithelial cells of mouse and human origin repressed LATS2 expression and increased YAP protein levels. LATS2 induction required binding of FOXP3 to a specific sequence in the LATS2 promoter, and this interaction contributed to FOXP3-mediated growth inhibition of tumor cells. In support of these results, reduced expression and somatic mutations of FOXP3 correlated strongly with defective LATS2 expression in microdissected prostate cancer tissues. Thus, defective expression of LATS2 is attributable to FOXP3 defects and may be a major independent determinant of YAP protein elevation in cancer. Our findings identify a novel mechanism of LATS2 downregulation in cancer and reveal an important tumor suppressor relay between the FOXP3 and HIPPO pathways which are widely implicated in human cancer.

Citing Articles

High clonal diversity and spatial genetic admixture in early prostate cancer and surrounding normal tissue.

Zhang N, Harbers L, Simonetti M, Diekmann C, Verron Q, Berrino E Nat Commun. 2024; 15(1):3475.

PMID: 38658552 PMC: 11043350. DOI: 10.1038/s41467-024-47664-z.

The Role of Tumor Microenvironment and Immune Response in Colorectal Cancer Development and Prognosis.

Wozniakova M, Skarda J, Raska M Pathol Oncol Res. 2022; 28:1610502.

PMID: 35936516 PMC: 9350736. DOI: 10.3389/pore.2022.1610502.

Integration of scRNA-Seq and TCGA RNA-Seq to Analyze the Heterogeneity of HPV+ and HPV- Cervical Cancer Immune Cells and Establish Molecular Risk Models.

Wei E, Reisinger A, Li J, French L, Clanner-Engelshofen B, Reinholz M Front Oncol. 2022; 12:860900.

PMID: 35719936 PMC: 9198569. DOI: 10.3389/fonc.2022.860900.

Contributes to TMZ Resistance, Prognosis, and Immune Infiltration in GBM from a Novel Pyroptosis-Associated Risk Signature.

Liang L, Yan B, Liu Y, Jiang S, He H, Huang J Dis Markers. 2022; 2022:4534080.

PMID: 35401877 PMC: 8993549. DOI: 10.1155/2022/4534080.

Dual CRISPR interference and activation for targeted reactivation of X-linked endogenous FOXP3 in human breast cancer cells.

Cui X, Zhang C, Xu Z, Wang S, Li X, Stringer-Reasor E Mol Cancer. 2022; 21(1):38.

PMID: 35130925 PMC: 8819949. DOI: 10.1186/s12943-021-01472-x.

References

Wu Y, Borde M, Heissmeyer V, Feuerer M, Lapan A, Stroud J . FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell. 2006; 126(2):375-87. DOI: 10.1016/j.cell.2006.05.042. View

McPherson J, Tamblyn L, Elia A, Migon E, Shehabeldin A, Matysiak-Zablocki E . Lats2/Kpm is required for embryonic development, proliferation control and genomic integrity. EMBO J. 2004; 23(18):3677-88. PMC: 517611. DOI: 10.1038/sj.emboj.7600371. View

St John M, Tao W, Fei X, Fukumoto R, Carcangiu M, Brownstein D . Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction. Nat Genet. 1999; 21(2):182-6. DOI: 10.1038/5965. View

Pan D . Hippo signaling in organ size control. Genes Dev. 2007; 21(8):886-97. DOI: 10.1101/gad.1536007. View

ONeill E, Kolch W . Taming the Hippo: Raf-1 controls apoptosis by suppressing MST2/Hippo. Cell Cycle. 2005; 4(3):365-7. DOI: 10.4161/cc.4.3.1531. View

Xu M, Yao T, Lee N, Ng I, Chan Y, Zender L . Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer. 2009; 115(19):4576-85. PMC: 2811690. DOI: 10.1002/cncr.24495. View

Zhao B, Wei X, Li W, Udan R, Yang Q, Kim J . Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007; 21(21):2747-61. PMC: 2045129. DOI: 10.1101/gad.1602907. View

Steinhardt A, Gayyed M, Klein A, Dong J, Maitra A, Pan D . Expression of Yes-associated protein in common solid tumors. Hum Pathol. 2008; 39(11):1582-9. PMC: 2720436. DOI: 10.1016/j.humpath.2008.04.012. View

Jimenez-Velasco A, Roman-Gomez J, Agirre X, Barrios M, Navarro G, Vazquez I . Downregulation of the large tumor suppressor 2 (LATS2/KPM) gene is associated with poor prognosis in acute lymphoblastic leukemia. Leukemia. 2005; 19(12):2347-50. DOI: 10.1038/sj.leu.2403974. View

10.

Harvey K, Tapon N . The Salvador-Warts-Hippo pathway - an emerging tumour-suppressor network. Nat Rev Cancer. 2007; 7(3):182-91. DOI: 10.1038/nrc2070. View

11.

Dai Z, Zhu W, Morrison C, Brena R, Smiraglia D, Raval A . A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes. Hum Mol Genet. 2003; 12(7):791-801. DOI: 10.1093/hmg/ddg083. View

12.

Wang Y, Dong Q, Zhang Q, Li Z, Wang E, Qiu X . Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci. 2010; 101(5):1279-85. PMC: 11158334. DOI: 10.1111/j.1349-7006.2010.01511.x. View

13.

Wang L, Liu R, Li W, Chen C, Katoh H, Chen G . Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell. 2009; 16(4):336-46. PMC: 2758294. DOI: 10.1016/j.ccr.2009.08.016. View

14.

Takahashi Y, Miyoshi Y, Takahata C, Irahara N, Taguchi T, Tamaki Y . Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res. 2005; 11(4):1380-5. DOI: 10.1158/1078-0432.CCR-04-1773. View

15.

Chen G, Chen C, Wang L, Chang X, Zheng P, Liu Y . Cutting edge: Broad expression of the FoxP3 locus in epithelial cells: a caution against early interpretation of fatal inflammatory diseases following in vivo depletion of FoxP3-expressing cells. J Immunol. 2008; 180(8):5163-6. PMC: 2527697. DOI: 10.4049/jimmunol.180.8.5163. View

16.

Zuo T, Wang L, Morrison C, Chang X, Zhang H, Li W . FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell. 2007; 129(7):1275-86. PMC: 1974845. DOI: 10.1016/j.cell.2007.04.034. View

17.

Jiang Z, Li X, Hu J, Zhou W, Jiang Y, Li G . Promoter hypermethylation-mediated down-regulation of LATS1 and LATS2 in human astrocytoma. Neurosci Res. 2006; 56(4):450-8. DOI: 10.1016/j.neures.2006.09.006. View

18.

Ladoire S, Arnould L, Mignot G, Coudert B, Rebe C, Chalmin F . Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 2010; 125(1):65-72. DOI: 10.1007/s10549-010-0831-1. View

19.

SOULE H, Maloney T, WOLMAN S, PETERSON Jr W, Brenz R, McGrath C . Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 1990; 50(18):6075-86. View

20.

Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford S . Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 2007; 130(6):1120-33. PMC: 2666353. DOI: 10.1016/j.cell.2007.07.019. View